Search Results

You are looking at 1 - 10 of 15 items for :

  • "Cancer-related anemia" x
Clear All
Full access

Jennifer M. Hinkel, Edward C. Li and Stephen L. Sherman

for the dialysis market and as Procrit by OrthoBiotech for other markets, including cancer and HIV/AIDS. In 1993, the FDA added an indication for cancer-related anemia as a label supplement for epoetin alfa (Epogen/Procrit), specifying that the

Full access

Jeffrey Crawford and George M. Rodgers

value of using intravenous (IV) iron for cancer-related anemia. Preventing FN FN, when brief and uncomplicated, has a low-risk mortality. However, the risk of death may increase to more than 20% in patients with major comorbidities. 1 Giving lower

Full access

Clinical and Operational Management of Cancer-Related Anemia Hinkel Jennifer M. MSc Li Edward C. PharmD, BCOP Sherman Stephen L. MBA 9 2010 8 8 Suppl_7 Suppl_7 S-38 S-38 S-55 S-55 008S-38 10.6004/jnccn.2010.0133

Full access

Edward C. Li

care. Second, a report discussing the clinical and operational challenges related to the management of cancer-related anemia details an NCCN Member Institution's initiative to reduce the use of blood products and also includes results from 3 different

Full access

John Glaspy

an increase in hemoglobin levels in patients with cancer-related anemia and, in those who were also receiving chemotherapy, treatment with erythropoiesis-stimulating agents (ESAs) was associated with a reduction in red cell transfusions. In 1989, the

Full access

John A. Glaspy

systemic, quantitative review . Cancer 2001 ; 91 : 2214 – 2221 . 48 Blohmer JU Dunst J Harrison L . Cancer-related anemia: biological findings, clinical implications and impact on quality of life . Oncology 2005 ; 1 : 12 – 21 . 49

Full access

Zhong Ye, Chun Wang, Limin Guo, Juan P. Palazzo, Zhixing Han, Yinzhi Lai, Jing Jiang, James A. Posey, Atrayee Basu Mallick, Bingshan Li, Li Jiang and Hushan Yang

combining multiple routine laboratory variables. Cancer-related anemia is due to multiple etiologies, including chemotherapy-induced myelosuppression, blood loss, functional iron deficiency, erythropoietin deficiency due to renal disease, marrow involvement

Full access

Jeffrey A. Gilreath and George M. Rodgers

. Gilreath JA Stenehjem DD Rodgers GM . Diagnosis and treatment of cancer-related anemia . Am J Hematol 2014 ; 89 : 203 – 212 . 7. Pfeiffer CM Johnson CL Jain RB . Trends in blood folate and vitamin B-12 concentrations in the United States

Full access

John A. Glaspy

Goss G . Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review . Cancer 2001 ; 91 : 2214 – 2221 . 92. Blohmer JU Dunst J Harrison L . Cancer-related anemia: biological findings

Full access

George M. Rodgers III, Pamela Sue Becker, Morey Blinder, David Cella, Asher Chanan-Khan, Charles Cleeland, Peter F. Coccia, Benjamin Djulbegovic, Jeffrey A. Gilreath, Eric H. Kraut, Ursula A. Matulonis, Michael M. Millenson, Denise Reinke, Joseph Rosenthal, Rowena N. Schwartz, Gerald Soff, Richard S. Stein, Gordana Vlahovic and Alva B. Weir III

-label study by Henry et al., 77 187 patients with cancer-related anemia receiving chemotherapy and epoetin alfa were randomized to no iron, oral ferrous sulfate 3 times daily, or weekly intravenous ferric gluconate. Intravenous iron produced a significantly